NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Direct to Consumer Advertising of Pharmaceutical Drugs: Information and Persuasion

Talia Bar, Dean R. Lillard

NBER Working Paper No. 19794
Issued in January 2014
NBER Program(s):   HE   IO

We formally model direct to consumer advertising (DTCA) of prescription drugs and examine factors that determine a pharmaceutical firm's DTCA strategy. We highlight how the profitability of DTCA varies with the characteristics of the condition that the advertised drug treats, the incidence of the condition, and the signal value of symptoms, and risk factors. We account for the potential information benefits from DTCA as well as its potential to persuade consumers. From a welfare perspective there can be too much or too little private investment in advertising. Welfare is more likely to increase when the population is uninsured.

download in pdf format
   (182 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w19794

Users who downloaded this paper also downloaded* these:
Dave and Saffer w15969 The Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand
Gaynor, Ho, and Town w19800 The Industrial Organization of Health Care Markets
David and Markowitz w17162 Side Effects of Competition: the Role of Advertising and Promotion in Pharmaceutical Markets
Dave w18830 Effects of Pharmaceutical Promotion: A Review and Assessment
Sinkinson and Starc w21045 Ask Your Doctor? Direct-to-Consumer Advertising of Pharmaceuticals
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us